Chee M Ng1,2, Erin Dombrowsky1, Hopi Lin1, Michelle E Erlich3, David E Moody4, Jeffrey S Barrett1,2, Walter K Kraft5. 1. Clinical Pharmacology and Therapeutics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 2. Department of Pediatrics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Pediatrics and Neurology, Mt. Sinai School of Medicine, New York, New York. 4. Center of Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah. 5. Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: Neonatal abstinence syndrome (NAS)--a clinical entity of infants from in utero exposure to psychoactive xenobiotic and buprenorphine--has been successfully used to treat NAS. However, nothing is known about the pharmacokinetics (PK) of buprenorphine in neonates with NAS. To our knowledge, this is the first study to investigate the population pharmacokinetic of sublingual buprenorphine in neonates with NAS. DESIGN: A retrospective population PK analysis of: (1) neonates with NAS treated with sublingual buprenorphine in randomized, double blinded clinical study and (2) data from healthy adults from a previously published pharmacokinetic study. SETTING: Neonatal intensive care unit and general clinical research unit. PATIENTS: Twenty-four neonates with NAS and five healthy adults. INTERVENTIONS: All participants received sublingual buprenorphine per study protocol. MEASUREMENTS AND MAIN RESULTS: A total of 303 PK data from 29 neonates and adults were used for model development. A population pharmacokinetic analysis was conducted using a first order conditional estimation with interaction in the NONMEM software program. A two-compartment linear PK model with first-order absorption process best described the pharmacokinetics of sublingual buprenorphine in neonates. The apparent clearance (CL) of buprenorphine was linearly related to body weight and matured with increasing age via two distinct saturated pathways. A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours. Phenobarbital did not affect the clearance of buprenorphine compared to neonates of similar age and weight. CONCLUSIONS: This is the first study to investigate the population PK of sublingual buprenorphine in neonatal NAS. To our knowledge, this is also the first report to describe the age-dependent changes of buprenorphine PK in this patient population. No buprenorphine dose adjustment is needed for neonates with NAS treated with buprenorphine and concurrent phenobarbital.
OBJECTIVE:Neonatal abstinence syndrome (NAS)--a clinical entity of infants from in utero exposure to psychoactive xenobiotic and buprenorphine--has been successfully used to treat NAS. However, nothing is known about the pharmacokinetics (PK) of buprenorphine in neonates with NAS. To our knowledge, this is the first study to investigate the population pharmacokinetic of sublingual buprenorphine in neonates with NAS. DESIGN: A retrospective population PK analysis of: (1) neonates with NAS treated with sublingual buprenorphine in randomized, double blinded clinical study and (2) data from healthy adults from a previously published pharmacokinetic study. SETTING: Neonatal intensive care unit and general clinical research unit. PATIENTS: Twenty-four neonates with NAS and five healthy adults. INTERVENTIONS: All participants received sublingual buprenorphine per study protocol. MEASUREMENTS AND MAIN RESULTS: A total of 303 PK data from 29 neonates and adults were used for model development. A population pharmacokinetic analysis was conducted using a first order conditional estimation with interaction in the NONMEM software program. A two-compartment linear PK model with first-order absorption process best described the pharmacokinetics of sublingual buprenorphine in neonates. The apparent clearance (CL) of buprenorphine was linearly related to body weight and matured with increasing age via two distinct saturated pathways. A typical neonate with NAS (body weight, 2.9 kg; postnatal age; 5.4 days) had a CL of 3.5 L/kg/hour and elimination half-life of 11 hours. Phenobarbital did not affect the clearance of buprenorphine compared to neonates of similar age and weight. CONCLUSIONS: This is the first study to investigate the population PK of sublingual buprenorphine in neonatal NAS. To our knowledge, this is also the first report to describe the age-dependent changes of buprenorphine PK in this patient population. No buprenorphine dose adjustment is needed for neonates with NAS treated with buprenorphine and concurrent phenobarbital.
Authors: Mette L Jensen; David J R Foster; Richard N Upton; Kim Kristensen; Steen H Hansen; Niels-Henrik Jensen; Bettina N Nielsen; Ulrik Skram; Hanne H Villesen; Lona Christrup Journal: Eur J Clin Pharmacol Date: 2007-09-16 Impact factor: 2.953
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford Journal: Br J Clin Pharmacol Date: 2006-07-21 Impact factor: 4.335
Authors: Eric C Strain; David E Moody; Kenneth B Stoller; Sharon L Walsh; George E Bigelow Journal: Drug Alcohol Depend Date: 2004-04-09 Impact factor: 4.492
Authors: Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft Journal: Clin Pharmacol Ther Date: 2018-04-28 Impact factor: 6.875
Authors: Walter K Kraft; Susan C Adeniyi-Jones; Inna Chervoneva; Jay S Greenspan; Diane Abatemarco; Karol Kaltenbach; Michelle E Ehrlich Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245
Authors: Tomoyuki Mizuno; Brooks T McPhail; Suyog Kamatkar; Scott Wexelblatt; Laura Ward; Uwe Christians; Henry T Akinbi; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2021-02 Impact factor: 6.447